WASHINGTON – Craig Burton has been promoted to senior vice president of policy and strategic alliances for the Association for Accessible Medicines (AAM), effective May 30. He will also become the executive director of the Biosimilars Council, which advocates at the federal and state levels for policies to improve access to more affordable alternatives to
WASHINGTON — In response to press reports on the current framework on prescription drug policies, AAM and its Biosimilars Council issued the following statement on the potential impact to patient access to generic and biosimilar medicines: “Patient access to more affordable generic and biosimilar medicines would be threatened under the policies currently under consideration in
WASHINGTON — The Association for Accessible Medicines (AAM) issued the following statement on the Senate Judiciary Committee’s Hearing on Pharmaceutical Competition: Thank you Chairwoman Klobuchar, Ranking Member Lee and members, of the Senate Judiciary’s Subcommittee on Antitrust for holding this important hearing and for the opportunity to submit this written statement on behalf of the
WASHINGTON — AAM and its Biosimilars Council commend the Administration for today’s effort to remove perverse rebate incentives now blocking competition in the U.S. prescription drug marketplace, but further action is necessary to modernize the Medicare Part D program and ensure that patients and taxpayers realize the full value of lower cost generic and biosimilar
WASHINGTON — Dan Leonard on Tuesday was named president and chief executive officer of the Association for Accessible Medicines. He will join AAM in September. He most recently served as president and CEO of the National Pharmaceutical Council (NPC), and succeeds Chester “Chip” Davis, Jr. who left AAM in February to head the Healthcare Distribution
WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics
The Association for Accessible Medicines (AAM) said a new report shows that abuse of the Food and Drug Administration’s Risk Evaluation Mitigation Strategies (REMS) safety program is hampering the market entry of new generic drugs. This week, AAM said a report by Alex Brill, CEO of economic policy consultancy Matrix Global Advisors, titled “REMS and
WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly
